Europska Unija - hrvatski - EMA (European Medicines Agency)

merck europe b.v. - cetrorelix (as acetate) - ovulation; ovulation induction - hipofiza i hipotalamusni hormoni i analozi - prevencija preuranjene ovulacije kod pacijenata koji su podvrgnuti kontroliranoj stimulaciji jajnika, nakon čega slijedi uzimanje oocita i pomoćno-reproduktivne tehnike. u kliničkim ispitivanjima, cetrotide koristi ljudski менопаузальный gonadotropin (hmg), međutim, ograničeno iskustvo primjenu rekombinantnog folikul stimulirajući (fsh) ponudili istu učinkovitost.

Europska Unija - hrvatski - EMA (European Medicines Agency)

n.v. organon - ganireliks - reproductive techniques, assisted; ovulation induction; infertility, female - hipofiza i hipotalamusni hormoni i analozi - prevencija preuranjenih luteinizirajućih hormonskih udara kod žena koje su pod kontrolom hiperstimulacije jajnika za pomoćne tehnike reprodukcije. u kliničkim studijama, orgalutran se koristio рекомбинантный ljudski фолликулостимулирующий hormon ili corifollitropin alfa, stalni stimulans dlake .

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

evropa lijek pharma d.o.o. - cetroreliks - prašak i rastvarač za rastvor za injekciju - 0,25 mg/1 ml - 1 ml rastvora za injekciju sadrži: 0,25 mg cetroreliksa (u obliku cetroreliks acetata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

glosarij cd d.o.o. sarajevo - cetroreliks - prašak i rastvarač za rastvor za injekciju - 0,25 mg/1 ml - 1 ml rastvora za injekciju sadrži: 0,25 mg cetroreliksa (u obliku cetroreliks acetata)

Europska Unija - hrvatski - EMA (European Medicines Agency)

chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hipofiza i hipotalamusni hormoni i analozi - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).

Europska Unija - hrvatski - EMA (European Medicines Agency)

theramex ireland limited - linzagolix choline - uterusa - hipofiza i hipotalamusni hormoni i analozi - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Europska Unija - hrvatski - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - uterusa - hipofiza i hipotalamusni hormoni i analozi - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

theramex ireland limited, 3rd floor, kilmore house, park lane, spencer dock, dublin, irska - ganireliksacetat - otopina za injekciju u napunjenoj štrcaljki - urbroj: jedna napunjena štrcaljka sadrži 0,25 mg ganireliksa (u obliku ganireliksacetata) u 0,5 ml vodene otopine

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Europska Unija - hrvatski - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinom, squamous cell - antineoplastična sredstva - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.